P3 Health Partners Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY AND MEZZANINE EQUITY

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY AND MEZZANINE EQUITY - USD ($) $ in Thousands	Total	Cumulative adjustment due to adoption of new credit loss standard	Class A Common Stock	Class V Common Stock	Redeemable Non-controlling Interest	Redeemable Non-controlling Interest Cumulative adjustment due to adoption of new credit loss standard	Common Stock Class A Common Stock	Common Stock Class V Common Stock	Additional Paid in Capital	Additional Paid in Capital Class V Common Stock	Accumulated Deficit	Accumulated Deficit Cumulative adjustment due to adoption of new credit loss standard
Increase (Decrease) in Stockholders' Equity
Beginning balance	$ 273,552						$ 4	$ 20	$ 312,946		$ (39,418)
Beginning balance at Dec. 31, 2021					$ 1,790,617
Increase (Decrease) in Temporary Equity
Equity-based compensation					17,618
Net loss					(1,291,430)
Ending balance at Dec. 31, 2022					516,805	$ (124)
Beginning balance (in shares) at Dec. 31, 2021							41,579,000	196,554
Increase (Decrease) in Stockholders' Equity
Vesting of Class V common stock awards (in shares)								5,038,000
Class A common stock warrants issued	643								643
Equity-based compensation	1,786								1,786
Net loss	(270,127)										(270,127)
Ending balance (in shares) at Dec. 31, 2022			41,579,000	201,592,000			41,579,000	201,592,000
Ending balance at Dec. 31, 2022	$ 5,854	$ (26)					$ 4	$ 20	315,375		(309,545)	$ (26)
Increase (Decrease) in Stockholders' Equity
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2016-13 [Member]
Beginning balance	$ 5,854	$ (26)					$ 4	$ 20	315,375		(309,545)	$ (26)
Equity-based compensation					785
Remeasurement adjustment to redeemable non-controlling interest resulting from ownership changes					(117,860)
Fair value adjustment to redeemable non-controlling interest					20,579
Net loss					(128,653)
Ending balance at Dec. 31, 2023					$ 291,532
Increase (Decrease) in Stockholders' Equity
Private placement, net of offering costs (in shares)							69,157,000
Private placement, net of offering costs	86,583						$ 7		86,576
At-the-market sales, net of offering costs	33						$ 27		33
Issuance of Class A common stock upon settlement of RSUs, net of shares withheld for tax (in shares)							204,000
Issuance of Class A common stock upon settlement of restricted stock units, net of shares withheld for tax	(16)								(16)
Restricted stock unit awards issued in satisfaction of executive transaction bonuses	5,000								5,000
Issuance of restricted stock awards (in shares)							250,000
Vesting of Class V common stock awards (in shares)								348,000
Vesting of Class V common stock awards	0							$ 1	(1)
Equity-based compensation	5,194								5,194
Exchanges of redeemable non-controlling interests for Class A common stock (in shares)							5,371,000	(5,371,000)
Exchanges of redeemable non-controlling interest for Class A common stock				$ 0			$ 1	$ (1)		$ 0
Remeasurement adjustment to redeemable non-controlling interest resulting from ownership changes	117,860								117,860
Fair value adjustment to redeemable non-controlling interest	(20,579)								(20,579)
Net loss	(57,773)										(57,773)
Ending balance (in shares) at Dec. 31, 2023			116,588,000	196,569,000			116,588,000	196,569,000
Ending balance at Dec. 31, 2023	142,130						$ 12	$ 20	509,442		(367,344)
Increase (Decrease) in Stockholders' Equity
Beginning balance	$ 142,130						$ 12	$ 20	$ 509,442		$ (367,344)